ACADEMIA

JAS 2012 GL Calls for Consideration of Medication for Primary Prevention in Patients with LDL-C Levels Over 180 mg/dL

February 7, 2012

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japan Atherosclerosis Society (JAS) announced at a forum held in Kagoshima City on February 5 the outline of the “prevention guideline (GL) for arteriosclerotic disease 2012”, for which the revision is in progress. The GL will indicate that medication…

To read the full story

New Atherosclerosis Guidelines Likely to Add PCSK9 Inhibitors for Primary Prevention of CAD in Familial Hypercholesterolemia
July 20, 2016

ACADEMIA

Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…